Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Arthritis, Lupus, Rheumatoid Arthritis, Cardiology, Cardiology, Cardiology, Infectious Disease, Endocrine, Gastrointestinal, Crohns Disease |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology, Gastroenterology, Immunology / Infectious Diseases, Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/2/2019 |
| Start Date: | January 25, 2016 |
| End Date: | January 25, 2022 |
The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases
This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography
(PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory
diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by
inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to
measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan
may help to determine how fluorine F 18 clofarabine is distributed throughout the body.
(PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory
diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by
inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to
measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan
may help to determine how fluorine F 18 clofarabine is distributed throughout the body.
PRIMARY OBJECTIVES:
I. Determine how fluorine F 18 clofarabine (18F‐clofarabine) is distributed in the body, in
patients with autoimmune and inflammatory diseases.
II. Determine whether 18F‐clofarabine can be used to image patients with autoimmune and
inflammatory diseases.
OUTLINE:
Patients receive fluorine F 18 clofarabine intravenously (IV) and undergo a single PET/CT
scan for up to 120 minutes.
I. Determine how fluorine F 18 clofarabine (18F‐clofarabine) is distributed in the body, in
patients with autoimmune and inflammatory diseases.
II. Determine whether 18F‐clofarabine can be used to image patients with autoimmune and
inflammatory diseases.
OUTLINE:
Patients receive fluorine F 18 clofarabine intravenously (IV) and undergo a single PET/CT
scan for up to 120 minutes.
Inclusion Criteria:
- Must be 18 years or older.
- Diagnosed with an autoimmune and inflammatory disorder.
Exclusion Criteria
- Women of childbearing age will have to undergo a pregnancy test that will be provided
free of charge.
- Patients unable to undergo or comply with PET/CT scanning due to pre-existing medical
conditions including claustrophobia.
We found this trial at
1
site
Los Angeles, California 90095
Principal Investigator: Martin Allen-Auerbach
Phone: 310-983-1444
Click here to add this to my saved trials
